Wellington Shields & Co. LLC Decreases Position in Merck & Co., Inc. (NYSE:MRK)

Wellington Shields & Co. LLC lessened its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 0.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,216 shares of the company’s stock after selling 200 shares during the quarter. Merck & Co., Inc. accounts for 0.8% of Wellington Shields & Co. LLC’s investment portfolio, making the stock its 25th biggest position. Wellington Shields & Co. LLC’s holdings in Merck & Co., Inc. were worth $2,608,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Tradewinds LLC. raised its position in Merck & Co., Inc. by 0.6% in the 3rd quarter. Tradewinds LLC. now owns 15,649 shares of the company’s stock worth $1,777,000 after purchasing an additional 101 shares during the period. CGN Advisors LLC grew its holdings in Merck & Co., Inc. by 0.4% in the 4th quarter. CGN Advisors LLC now owns 26,969 shares of the company’s stock worth $2,683,000 after acquiring an additional 102 shares during the last quarter. Accredited Investors Inc. grew its holdings in Merck & Co., Inc. by 0.9% in the 3rd quarter. Accredited Investors Inc. now owns 11,834 shares of the company’s stock worth $1,344,000 after acquiring an additional 109 shares during the last quarter. Cypress Wealth Services LLC grew its holdings in Merck & Co., Inc. by 3.1% in the 4th quarter. Cypress Wealth Services LLC now owns 3,639 shares of the company’s stock worth $362,000 after acquiring an additional 111 shares during the last quarter. Finally, TI Trust Inc. grew its holdings in Merck & Co., Inc. by 0.6% in the 4th quarter. TI Trust Inc. now owns 19,834 shares of the company’s stock worth $1,973,000 after acquiring an additional 111 shares during the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 0.0 %

NYSE:MRK opened at $94.72 on Friday. Merck & Co., Inc. has a one year low of $81.04 and a one year high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company’s 50-day simple moving average is $93.57 and its 200 day simple moving average is $101.99. The firm has a market capitalization of $239.27 billion, a P/E ratio of 14.07, a PEG ratio of 0.77 and a beta of 0.35.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by ($0.13). The business had revenue of $15.62 billion for the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The company’s revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.03 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. declared that its board has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 4.1% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its shares are undervalued.

Merck & Co., Inc. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Shareholders of record on Monday, March 17th will be issued a $0.81 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 48.14%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, insider Cristal N. Downing sold 2,361 shares of Merck & Co., Inc. stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $88.76, for a total value of $209,562.36. Following the completion of the transaction, the insider now directly owns 7,085 shares of the company’s stock, valued at approximately $628,864.60. The trade was a 24.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Inge G. Thulin bought 2,833 shares of the firm’s stock in a transaction on Thursday, February 6th. The stock was purchased at an average cost of $88.25 per share, with a total value of $250,012.25. Following the completion of the acquisition, the director now directly owns 2,933 shares of the company’s stock, valued at approximately $258,837.25. The trade was a 2,833.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on MRK. Hsbc Global Res raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 4th. TD Securities lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price target for the stock from $121.00 to $100.00 in a report on Monday, February 10th. Truist Financial reissued a “hold” rating and issued a $110.00 price target (down previously from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. TD Cowen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their price target for the stock from $121.00 to $100.00 in a report on Monday, February 10th. Finally, Citigroup cut their target price on shares of Merck & Co., Inc. from $125.00 to $115.00 and set a “buy” rating on the stock in a research note on Wednesday, February 5th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $117.12.

View Our Latest Stock Analysis on Merck & Co., Inc.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.